Jiangsu Hengrui Medicine
600276.SS
#389
Rank
C$81.05 B
Marketcap
C$12.21
Share price
1.36%
Change (1 day)
27.50%
Change (1 year)
Jiangsu Hengrui Medicine Company Limited is a Chinese pharmaceutical company engaged in the R&D, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics

Earnings for Jiangsu Hengrui Medicine (600276.SS)

Earnings in 2025 (TTM): C$1.64 Billion

According to Jiangsu Hengrui Medicine 's latest financial reports the company's current earnings are C$4.19 Billion. In 2024 the company made an earning of C$1.37 Billion, an increase over its 2023 earnings that were of C$0.91 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Jiangsu Hengrui Medicine from 2002 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) C$1.64 B19.83%
2024 C$1.37 B50.59%
2023 C$0.91 B11.35%
2022 C$0.81 B-13.82%
2021 C$0.95 B-34.16%
2020 C$1.44 B16.28%
2019 C$1.24 B32.92%
2018 C$0.93 B20.82%
2017 C$0.77 B23.8%
2016 C$0.62 B11.25%
2015 C$0.56 B39.52%
2014 C$0.40 B20.71%
2013 C$0.33 B11.46%
2012 C$0.29 B29.6%
2011 C$0.23 B31.28%
2010 C$0.17 B27.89%
2009 C$0.13 B5.84%
2008 C$0.12 B79.89%
2007 C$72.19 M32.93%
2006 C$54.31 M38.14%
2005 C$39.31 M21.56%
2004 C$32.34 M13.95%
2003 C$28.38 M38.06%
2002 C$20.55 M